Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.38 +2.1%	$0.38	$0.22 ▼ $1.30	$8.12M	1	3.64 million shs	685,614 shs
CLSD Clearside Biomedical	$0.41 +1.0%	$0.61	$0.29 ▼ $1.65	$31.64M	2.08	880,619 shs	364,782 shs
MURA Mural Oncology	$2.08 +0.5%	$2.27	$0.95 ▼ $4.74	$35.86M	3	551,494 shs	435,374 shs
SNYR Synergy CHC	$2.94 +1.4%	$3.23	$1.19 ▼ $10.00	$27.38M	N/A	47,397 shs	80,384 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+2.15%	-3.53%	-20.60%	-44.90%	-61.21%
CLSD Clearside Biomedical	+1.04%	-3.74%	-30.39%	-52.82%	-59.68%
MURA Mural Oncology	+0.48%	+18.18%	-16.13%	-24.36%	-36.78%
SNYR Synergy CHC	+1.38%	-14.29%	-20.54%	+50.00%	+9,700.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	1.7918 of 5 stars	3.5	2.0	1.8	0.0	0.6
CLSD Clearside Biomedical	1.8693 of 5 stars	4.1	3.0	0.6	0.0	0.0
MURA Mural Oncology	2.9645 of 5 stars	3.3	3.0	1.8	2.5	1.3
SNYR Synergy CHC	4.268 of 5 stars	3.8	0.0	2.2	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.00	Buy	$8.00	2,004.71% Upside
CLSD Clearside Biomedical	2.17	Hold	$4.20	931.43% Upside
MURA Mural Oncology	2.50	Moderate Buy	$12.00	476.92% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	240.14% Upside

Current Analyst Ratings Breakdown

Latest ADIL, CLSD, SNYR, and MURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	ADIL Adial Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/18/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
7/18/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/18/2025	CLSD Clearside Biomedical	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00
7/17/2025	CLSD Clearside Biomedical	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$3.00
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.26 per share	N/A
CLSD Clearside Biomedical	$1.66M	19.26	N/A	N/A	($0.62) per share	-0.66
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A
SNYR Synergy CHC	$34.83M	0.80	$0.27 per share	10.90	($1.31) per share	-2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.05	N/A	N/A	N/A	N/A	-191.31%	-153.59%	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.37	N/A	N/A	N/A	-665.19%	N/A	-124.15%	11/11/2025 (Estimated)
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A
SNYR Synergy CHC	$2.12M	$0.38	7.74	4.98	N/A	10.02%	-18.56%	20.28%	N/A

Latest ADIL, CLSD, SNYR, and MURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/13/2025	Q2 2025	ADIL Adial Pharmaceuticals	-$0.22	-$0.18	+$0.04	-$0.18	N/A	N/A
8/8/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	-$0.06	+$0.06	-$0.06	$0.50 million	$0.49 million
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.02	5.02
CLSD Clearside Biomedical	N/A	3.87	3.87
MURA Mural Oncology	N/A	2.87	2.87
SNYR Synergy CHC	N/A	2.74	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CLSD Clearside Biomedical	18.75%
MURA Mural Oncology	80.21%
SNYR Synergy CHC	N/A

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
CLSD Clearside Biomedical	6.70%
MURA Mural Oncology	2.20%
SNYR Synergy CHC	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	21.83 million	20.90 million	No Data
CLSD Clearside Biomedical	30	78.51 million	73.25 million	Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A

ADIL, CLSD, SNYR, and MURA Headlines

Recent News About These Companies

Synergy CHC's (NASDAQ:SNYR) Earnings Quality Is Low

August 22 at 10:03 AM | finance.yahoo.com

Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th

August 21 at 9:40 AM | markets.businessinsider.com

New to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...

August 20 at 6:38 PM | palmbeachpost.comP

Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

August 18, 2025 | taiwannews.com.twT

New to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...

August 18, 2025 | finanznachrichten.de

Synergy CHC announces major distribution with for FOCUSfactor Focus + Energy

August 18, 2025 | msn.com

Synergy CHC Expands FOCUSfactor Distribution with EG America

August 18, 2025 | tipranks.com

Analysts Set Expectations for Synergy CHC FY2025 Earnings

August 18, 2025 | americanbankingnews.com

Synergy CHC files to sell 1.28M shares of common stock

August 15, 2025 | msn.com

Synergy Chc EPS Jumps 86 Percent in Q2

August 15, 2025 | theglobeandmail.com

Synergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | finanznachrichten.de

Synergy CHC reports Q2 EPS 17c vs 9c last year

August 14, 2025 | msn.com

Synergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year Growth

August 14, 2025 | quiverquant.comQ

Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

August 14, 2025 | globenewswire.com

New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion Rate

August 5, 2025 | indystar.comI

New to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market Saturation

August 5, 2025 | desmoinesregister.comD

Jack Ross Buys Handful Of Shares In Synergy CHC

August 3, 2025 | finance.yahoo.com

Insider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of Stock

August 1, 2025 | insidertrades.com

Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

July 31, 2025 | manilatimes.netM

Synergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution Expansion

July 31, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL, CLSD, SNYR, and MURA Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.38 +0.01 (+2.15%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.37 -0.01 (-2.66%)

As of 08/22/2025 07:57 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Clearside Biomedical NASDAQ:CLSD

$0.41 +0.00 (+1.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.40 -0.01 (-3.00%)

As of 08/22/2025 07:54 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Mural Oncology NASDAQ:MURA

$2.08 +0.01 (+0.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.07 -0.01 (-0.48%)

As of 08/22/2025 07:26 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Synergy CHC NASDAQ:SNYR

$2.94 +0.04 (+1.38%)

As of 08/22/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time